Shandong Sito Bio-technology Co., Ltd.

300583

CNE100002F36

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
14.26 ^CNY	-1.25%		-8.53%	-27.91%

08/05	Shandong Sito Bio-technology Gets European Suitability Certification for Rhinitis Nasal Spray	MT
28/04	Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shandong Sito Bio-Technology Co., Ltd. Proposes Final Dividend for 2021

April 27, 2022 at 01:07 am IST

Shandong Sito Bio-technology Co., Ltd. proposed final Cash dividend/10 shares (tax included): CNY 0.15000000 for 2021.

Latest news about Shandong Sito Bio-technology Co., Ltd.

Shandong Sito Bio-technology Gets European Suitability Certification for Rhinitis Nasal Spray	08/05	MT
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28/04	CI
Shandong Sito Bio-Technology Co., Ltd. Appoints Kang Li as Independent Director	11/12	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	20/23/20	CI
Shandong Sito Bio-technology in Talks to Buy 60% of Local Steroid Maker for 46 Million Yuan	16/23/16	MT
Shandong Sito Bio-technology Co., Ltd. agreed to acquire 60% stake in Yingu Pharmaceutical Co., Ltd. from Yingu Holding Group for approximately CNY 460 million.	16/23/16	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Shandong Sito Bio-Technology Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 28 June 2023	18/23/18	CI
Shandong Sito Bio-technology Co., Ltd. Proposes Final Cash Dividend for 2022	26/23/26	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	18/23/18	CI
Shandong Sito Bio-technology Co., Ltd. announced that it has received CNY 261.590392 million in funding from a group of investors	07/23/07	CI
Sito Bio-technology Selling 300 Million Yuan Shares to Fund New Factory	13/23/13	MT
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	19/22/19	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Shandong Sito Bio-Technology Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022	29/22/29	CI
Shandong Sito Bio-technology Co., Ltd. announced that it expects to receive CNY 298.0822 million in funding from a group of investors	25/22/25	CI
Shandong Sito Bio-technology Co., Ltd. Approves Cash Dividend for the Year 2021	24/22/24	CI
Shandong Sito Bio-Technology Co., Ltd. Proposes Final Dividend for 2021	27/22/27	CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	25/22/25	CI
Shandong Sito Bio-technology Co., Ltd. cancelled the transaction announced on July 16, 2021	05/22/05	CI
Junlanghui Enterprise Management Partnership (Limited Partnership) signed a share transfer agreement to acquire a 5% stake in Shandong Sito Bio-technology Co., Ltd. (SZSE : 300583) from Shandong Runxin Investment Co., Ltd. for approximately CNY 140 million.	08/22/08	CI
Chinese cities ease home purchase down-payments to reignite demand	18/22/18	RE
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	28/21/28	CI
Shandong Sito Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/21/27	CI

Chart Shandong Sito Bio-technology Co., Ltd.

Duration

Period

Chart Shandong Sito Bio-technology Co., Ltd.

More charts

Shandong Sito Bio-technology Co Ltd is a company that provides raw materials for pharmaceutical companies. The Company operates three product segments. The Steroid Raw Materials segment is engaged in the manufacturing of steroid raw materials using genetic engineering technology and microbial transformation technology, such as androstenedione, androstenedione, 9-hydroxyandrostenedione, hydroxyprogesterone and so on. The Company also operates Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment through its subsidiary.

Sector

Pharmaceuticals

Calendar

21/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.26

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG SITO BIO-TECHNOLOGY CO., LTD.	-27.91%	37Cr
ELI LILLY AND COMPANY	+32.09%	69TCr
NOVO NORDISK A/S	+29.39%	58TCr
JOHNSON & JOHNSON	-1.34%	37TCr
MERCK & CO., INC.	+20.34%	33TCr
ABBVIE INC.	+7.39%	29TCr
ASTRAZENECA PLC	+14.25%	24TCr
ROCHE HOLDING AG	-3.03%	21TCr
NOVARTIS AG	+10.02%	21TCr
AMGEN INC.	+8.49%	17TCr

Other Pharmaceuticals